Actimed Therapeutics Announces US FDA Grant of Orphan Drug Designation to S-oxprenolol (ACM-002) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Actimed Therapeutics Ltd. announced that the US FDA has granted Orphan Drug Designation to S-oxprenolol for the treatment of ALS. In pre-clinical ALS models, S-oxprenolol has demonstrated benefits including slowing disease progression, improvement in survival, and motor neuron protection.